Cellectar Biosciences, Inc. (CLRB) surged 24.03 percent to $3.51 after gaining $0.68 on Tuesday, following the announcement of updated and mature clinical trial results for its cancer therapy candidate.
The stock is currently trading at $3.51, compared to a previous close of $2.83 on the Nasdaq. It opened at $4.50 and traded between $3.43 and $4.70 during the session, with volume reaching 45.74 million shares.
Following positive 12-month follow-up data from its Phase 2b CLOVER WaM trial, which showed high response rates and durable efficacy for iopofosine I 131 in heavily pretreated patients, strengthening its case for potential accelerated regulatory approval.
The stock has traded between $2.43 and $20.70 over the past 52 weeks.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.